Literature DB >> 20061536

Agonist monoclonal antibodies against HGF receptor protect cardiac muscle cells from apoptosis.

Stefano Pietronave1, Giancarlo Forte, Deborah Locarno, Simone Merlin, Andrea Zamperone, Giuseppina Nicotra, Ciro Isidoro, Paolo Di Nardo, Maria Prat.   

Abstract

Hepatocyte growth factor (HGF), a pleiotropic cytokine with mitogenic, motogenic, morphogenic, and antiapoptotic effects in various cell types, is a cardioprotective growth factor that can counteract the loss of cardiomyocytes usually observed in cardiac diseases. HGF is a quite unstable molecule in its biologically active heterodimeric form. Since all HGF-induced biological responses are mediated by its high-affinity tyrosine kinase receptor (Met/HGF-R) encoded by the Met gene, we asked whether a monoclonal antibody (MAb) that displays receptor full agonist activity could protect cardiac muscle cell lines from hydrogen peroxide-induced apoptosis. We report that the MAb efficiently inhibited hydrogen peroxide-induced cell shrinkage, DNA fragmentation, annexin V positivity, mitochondrial translocation of bax, and caspase activation. The MAb was thus able to counteract apoptosis evaluated by both morphological and biochemical criteria. The agonist activity of the MAb was mediated by Met/HGF-R, since a Met/HGF-R-specific short hairpin RNA (shRNA) inhibited both activation of transduction pathways and motility triggered by MAb DO-24. The protective antiapoptotic effect of MAb DO-24 was dependent on activation of the ras-MAPK Erk1/2 and phosphatidylinositol 3-kinase (PI3-kinase)-Akt transduction pathways, since it was abrogated by treatments with their specific pharmacological inhibitors, PD-98059 and wortmannin. Moreover, the MAb induced a motogenic, but not mitogenic, response in these cells, mimicking in all aspects the natural ligand HGF but displaying a significant higher stability than HGF in culture. This MAb may thus be a valuable substitute for HGF, being more easily available in a biologically active, highly stable, and purified form.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061536     DOI: 10.1152/ajpheart.01323.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  14 in total

Review 1.  Towards the generation of patient-specific patches for cardiac repair.

Authors:  Giancarlo Forte; Stefania Pagliari; Francesca Pagliari; Mitsuhiro Ebara; Paolo Di Nardo; Takao Aoyagi
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

2.  An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist.

Authors:  Cassie J Liu; Douglas S Jones; Ping-Chuan Tsai; Abhishek Venkataramana; Jennifer R Cochran
Journal:  FEBS Lett       Date:  2014-11-21       Impact factor: 4.124

Review 3.  Novel therapy for myocardial infarction: can HGF/Met be beneficial?

Authors:  V Sala; T Crepaldi
Journal:  Cell Mol Life Sci       Date:  2011-02-17       Impact factor: 9.261

4.  SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models.

Authors:  Chang-Yong Yang; Lei Wang; Xing Sun; Mi Tang; Hai-Tian Quan; Lian-Shan Zhang; Li-Guang Lou; Shao-Hua Gou
Journal:  Acta Pharmacol Sin       Date:  2019-01-14       Impact factor: 6.150

5.  Gene expression profiling of HGF/Met activation in neonatal mouse heart.

Authors:  Stefano Gatti; Christian Leo; Simona Gallo; Valentina Sala; Enrico Bucci; Massimo Natale; Daniela Cantarella; Enzo Medico; Tiziana Crepaldi
Journal:  Transgenic Res       Date:  2012-12-06       Impact factor: 2.788

Review 6.  Understanding cytokine and growth factor receptor activation mechanisms.

Authors:  Mariya Atanasova; Adrian Whitty
Journal:  Crit Rev Biochem Mol Biol       Date:  2012-10-09       Impact factor: 8.250

7.  Human Cardiac Progenitor Spheroids Exhibit Enhanced Engraftment Potential.

Authors:  Francesca Oltolina; Andrea Zamperone; Donato Colangelo; Luca Gregoletto; Simone Reano; Stefano Pietronave; Simone Merlin; Maria Talmon; Eugenio Novelli; Marco Diena; Carmine Nicoletti; Antonio Musarò; Nicoletta Filigheddu; Antonia Follenzi; Maria Prat
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

8.  Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.

Authors:  Jieyi Wang; Liliane Goetsch; Lora Tucker; Qian Zhang; Alexandra Gonzalez; Kedar S Vaidya; Anatol Oleksijew; Erwin Boghaert; Minghao Song; Irina Sokolova; Ekaterina Pestova; Mark Anderson; William N Pappano; Peter Ansell; Anahita Bhathena; Louie Naumovski; Nathalie Corvaia; Edward B Reilly
Journal:  BMC Cancer       Date:  2016-02-16       Impact factor: 4.430

Review 9.  HGF and MET: From Brain Development to Neurological Disorders.

Authors:  Claudia Desole; Simona Gallo; Annapia Vitacolonna; Francesca Montarolo; Antonio Bertolotto; Denis Vivien; Paolo Comoglio; Tiziana Crepaldi
Journal:  Front Cell Dev Biol       Date:  2021-06-09

10.  Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy.

Authors:  S Gallo; S Gatti; V Sala; R Albano; P Costelli; E Casanova; P M Comoglio; T Crepaldi
Journal:  Cell Death Dis       Date:  2014-04-17       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.